Anvumetostat

DRUG2 trials

Sponsors

Amgen

Conditions

Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersAdvanced MTAP-null Solid Tumors

Phase 1

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Active, not recruitingNCT05094336

AmgenAdvanced MTAP-null Solid Tumors

Start: 2022-02-01End: 2028-05-29Updated: 2026-03-31

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

RecruitingNCT06360354

AmgenAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Start: 2024-05-29End: 2029-02-25Target: 350Updated: 2026-03-31

Related Papers

Abstract 7065: Targeting MTAP-deleted/KRAS mutant cancers using RAS inhibitors in combination with AMG 193, an MTA-cooperative PRMT5 inhibitor.

Cancer Research2026-04-03

Abstract B177: The discovery and preclinical characterization of AMG 193, a first-in-class MTA-cooperative PRMT5 inhibitor with broad activity against <i>MTAP</i>-null cancers

Molecular Cancer Therapeutics2023-12-015 citations

Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.

Journal of Clinical Oncology2022-06-0110 citations